α-Synuclein: membrane interactions and toxicity in Parkinson's disease.
暂无分享,去创建一个
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] Clare M Waterman,et al. Mechanical integration of actin and adhesion dynamics in cell migration. , 2010, Annual review of cell and developmental biology.
[3] C. Desplan,et al. Stochastic mechanisms of cell fate specification that yield random or robust outcomes. , 2010, Annual review of cell and developmental biology.
[4] W. Wickner. Membrane fusion: five lipids, four SNAREs, three chaperones, two nucleotides, and a Rab, all dancing in a ring on yeast vacuoles. , 2010, Annual review of cell and developmental biology.
[5] Peter McCourt,et al. Plant nuclear hormone receptors: a role for small molecules in protein-protein interactions. , 2010, Annual review of cell and developmental biology.
[6] Frederick Grinnell,et al. Cell motility and mechanics in three-dimensional collagen matrices. , 2010, Annual review of cell and developmental biology.
[7] Heidi N. Fridolfsson,et al. Interactions between nuclei and the cytoskeleton are mediated by SUN-KASH nuclear-envelope bridges. , 2010, Annual review of cell and developmental biology.
[8] J. Hay,et al. α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs , 2010, Molecular biology of the cell.
[9] Joshua A. Kritzer,et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models , 2010, Disease Models & Mechanisms.
[10] Kwang-Soo Kim,et al. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. , 2010, Experimental cell research.
[11] R. Nicoll,et al. Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.
[12] O. Isacson,et al. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression , 2009, Proceedings of the National Academy of Sciences.
[13] Yusuke Nakamura,et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.
[14] Thomas Gasser,et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.
[15] A. Nohturfft,et al. Coordination of lipid metabolism in membrane biogenesis. , 2009, Annual review of cell and developmental biology.
[16] Tatiana Foroud,et al. Genomewide association study for onset age in Parkinson disease , 2009, BMC Medical Genetics.
[17] R. Cappai,et al. The Molecular Chaperone Hsp90 Modulates Intermediate Steps of Amyloid Assembly of the Parkinson-related Protein α-Synuclein* , 2009, The Journal of Biological Chemistry.
[18] Connie Marras,et al. Occupation and risk of parkinsonism: a multicenter case-control study. , 2009, Archives of neurology.
[19] H. Stenmark. Rab GTPases as coordinators of vesicle traffic , 2009, Nature Reviews Molecular Cell Biology.
[20] Aj Lees,et al. Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .
[21] Peter Walter,et al. Supporting Online Material for An ER-Mitochondria Tethering Complex Revealed by a Synthetic Biology Screen , 2009 .
[22] A. Singleton,et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.
[23] M. Kreft,et al. Sphingosine Facilitates SNARE Complex Assembly and Activates Synaptic Vesicle Exocytosis , 2009, Neuron.
[24] H. Lashuel,et al. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.
[25] Victor Tapias,et al. A highly reproducible rotenone model of Parkinson's disease , 2009, Neurobiology of Disease.
[26] D. Sulzer,et al. Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.
[27] M. Stampfer. Welding Occupations and Mortality from Parkinson's Disease and Other Neurodegenerative Diseases Among United States Men, 1985–1999 , 2009, Journal of occupational and environmental hygiene.
[28] M. Hasegawa,et al. Conversion of Wild-type α-Synuclein into Mutant-type Fibrils and Its Propagation in the Presence of A30P Mutant* , 2009, Journal of Biological Chemistry.
[29] Jason D. Perlmutter,et al. Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. , 2009, The Journal of biological chemistry.
[30] D. Karger,et al. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity , 2009, Nature Genetics.
[31] S. Lindquist,et al. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.
[32] L. Scorrano,et al. Mitofusin 2 tethers endoplasmic reticulum to mitochondria , 2008, Nature.
[33] A. Ariza,et al. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. , 2008, Current medicinal chemistry.
[34] T. Iwatsubo,et al. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. , 2008, Human molecular genetics.
[35] A. Elbaz,et al. Update in the epidemiology of Parkinson's disease , 2008, Current opinion in neurology.
[36] P. Emson,et al. Altered vesicular dopamine storage in Parkinson's disease: a premature demise , 2008, Trends in Neurosciences.
[37] Xuemei Huang,et al. Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[38] M. Ripoli,et al. Mitochondrial Respiratory Dysfunction in Familiar Parkinsonism Associated with PINK1 Mutation , 2008, Neurochemical Research.
[39] F. Giorgini,et al. Yeast as a model for studying human neurodegenerative disorders , 2008, Biotechnology journal.
[40] Sonja W. Scholz,et al. Genomewide SNP assay reveals mutations underlying Parkinson disease , 2008, Human mutation.
[41] S. Lindquist,et al. The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis , 2008, Proceedings of the National Academy of Sciences.
[42] J. Trojanowski,et al. Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. , 2007, Molecular biology of the cell.
[43] Koichi Abe,et al. Peptide ligand screening of α-synuclein aggregation modulators by in silico panning , 2007, BMC Bioinformatics.
[44] Kara Dolinski,et al. Gene Ontology annotations at SGD: new data sources and annotation methods , 2007, Nucleic Acids Res..
[45] S. Lindquist,et al. Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.
[46] D. Perl,et al. The Neuropathology of Manganese-Induced Parkinsonism , 2007, Journal of neuropathology and experimental neurology.
[47] Lewis E Kazis,et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.
[48] B. Davletov,et al. Regulation of SNARE fusion machinery by fatty acids , 2007, Cellular and Molecular Life Sciences.
[49] M. Feany,et al. Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo , 2007, The Journal of Neuroscience.
[50] J. Trojanowski,et al. Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model , 2007 .
[51] N. Scott,et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study , 2007, Occupational and Environmental Medicine.
[52] Kevin R. Sanft,et al. Chemical exposures and Parkinson's disease: A population‐based case–control study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[53] Kexiang Xu,et al. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging , 2006, Proceedings of the National Academy of Sciences.
[54] W. Balch,et al. The Hsp90 chaperone complex regulates GDI-dependent Rab recycling. , 2006, Molecular biology of the cell.
[55] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[56] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[57] R. Nass,et al. Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein , 2006, Neurobiology of Disease.
[58] F. Kamp,et al. Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.
[59] F. Giorgini,et al. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases , 2006, Biotechnology journal.
[60] S. Lindquist,et al. HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.
[61] M. Beal,et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[62] C. A. Froelich,et al. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. , 2005, Journal of molecular biology.
[63] P. Auluck,et al. Mechanisms of Suppression of α-Synuclein Neurotoxicity by Geldanamycin in Drosophila* , 2005, Journal of Biological Chemistry.
[64] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[65] J. Allman,et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.
[66] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[67] G. Mardon,et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.
[68] T. Gómez-Isla,et al. Abnormal α‐Synuclein Interactions with Rab Proteins in α‐Synuclein A30P Transgenic Mice , 2004 .
[69] Diego Guidolin,et al. α‐Synuclein and Parkinson's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[70] T. Gómez-Isla,et al. Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. , 2004, Journal of neuropathology and experimental neurology.
[71] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[72] S. Lindquist,et al. Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.
[73] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[74] Clemens R Scherzer,et al. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. , 2003, Human molecular genetics.
[75] B. Giasson,et al. Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.
[76] R. Blakely,et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.
[77] David W. Miller,et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.
[78] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[79] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[80] W. Balch,et al. Rab‐αGDI activity is regulated by a Hsp90 chaperone complex , 2002 .
[81] P. Auluck,et al. Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.
[82] Nutan Sharma,et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.
[83] Richard Paylor,et al. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.
[84] Nancy A. Jenkins,et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[85] J. Trojanowski,et al. Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.
[86] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[87] R. Perrin,et al. Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.
[88] D. Eliezer,et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.
[89] J Q Trojanowski,et al. A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.
[90] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[91] A. Brice,et al. Alpha-synuclein and Parkinson's disease , 2000, Cellular and Molecular Life Sciences CMLS.
[92] P. S. St George-Hyslop,et al. α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.
[93] R. Perrin,et al. Interaction of Human α-Synuclein and Parkinson's Disease Variants with Phospholipids , 2000, The Journal of Biological Chemistry.
[94] M. Citron,et al. Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs* , 2000, The Journal of Biological Chemistry.
[95] J. Trojanowski,et al. Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.
[96] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[97] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[98] J. Trojanowski,et al. Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.
[99] N. Taylor,et al. Could mitochondrial dysfunction play a role in manganese toxicity? , 1999, Environmental toxicology and pharmacology.
[100] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[101] C. Lavedan. The synuclein family. , 1998, Genome research.
[102] Nigel J. Cairns,et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.
[103] Makoto Hashimoto,et al. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.
[104] A. Jonas,et al. Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.
[105] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[106] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[107] J. Vance,et al. Import of lipids into mitochondria. , 1997, Progress in lipid research.
[108] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[109] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[110] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[111] M. Kozlov,et al. Lipids in biological membrane fusion , 1995, The Journal of Membrane Biology.
[112] H. Przuntek,et al. Increased Risk of Parkinson's Disease in Relatives of Patients , 1995, Annals of neurology.
[113] J. Kimura,et al. Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains , 1994, Brain Research.
[114] G. Anantharamaiah,et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. , 1992, Journal of lipid research.
[115] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[116] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[117] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[118] L T Smyth,et al. Clinical manganism and exposure to manganese in the production and processing of ferromanganese alloy. , 1973, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[119] P. Mueller,et al. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa , 1971, Clinical pharmacology and therapeutics.
[120] W. A. Jager,et al. Sphingomyelin in Lewy inclusion bodies in Parkinson's disease. , 1969 .
[121] A. Destée,et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. , 2009, Archives of neurology.
[122] H. Lashuel,et al. E 46 K Parkinson ’ sLinked Mutation Enhances C-Terminal-toN-Terminal Contacts in α-Synuclein , 2009 .
[123] J. Cano,et al. Mitochondrial toxins and neurodegenerative diseases. , 2007, Frontiers in bioscience : a journal and virtual library.
[124] C. Marsden,et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[125] H De Loof,et al. Amphipathic helix motif: Classes and properties , 1990, Proteins.
[126] P. Riekkinen,et al. Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. , 1975, Archives of neurology.